Safety and efficacy of fruquintinib‐based therapy in patients with advanced or metastatic sarcoma

Abstract

AbstractBackgroundThe purpose of this study was to evaluate the efficacy and safety of fruquintinib‐based therapy as a salvage therapy for patients with advanced or metastatic sarcoma, including soft tissue sarcoma (STS) and bone sarcoma.MethodsPatients with advanced or metastatic sarcoma were divided into two groups. One group received fruquintinib monotherapy, while the other received fruquintinib combined therapy. Safety and efficacy of fruquintinib‐based therapy were recorded and reviewed retrospectively, including progression‐free survival (PFS), overall response rate (ORR), and adverse events (AEs).ResultsBetween August 2021 and December 2022, 38 sarcoma patients were retrospectively included. A total of 14 patients received fruquintinib alone (including 6 STS and 8 bone sarcoma), while 24 were treated with fruquintinib combined therapy (including 2 STS and 22 bone sarcoma). The median follow‐up was 10.2 months (95% CI, 6.4–11.5). For the entire population, the median PFS was 8.0 months (95% CI, 5.5–13.0). The ORR was 13.1%, while the disease control rate (DCR) was 86.8%. The univariate analysis showed that radiotherapy history (HR, 4.56; 95% CI, 1.70–12.24; p = 0.003), bone sarcoma (HR, 0.34; 95% CI, 0.14–0.87; p = 0.024), and treatment method of fruquintinib (HR, 0.36; 95% CI, 0.15–0.85; p = 0.021) were significantly associated with PFS. The multivariate analysis showed that patients without radiotherapy history were associated with a better PFS (HR, 3.71; 95% CI: 1.31–10.55; p = 0.014) than patients with radiotherapy history. Patients in combination group reported pneumothorax (8.3%), leukopenia (33.3%), thrombocytopenia (12.5%), diarrhea (4.2%), and anemia (4.2%) as the most frequent grade 3 or higher treatment‐emergent AEs (TEAEs), while there was no severe TEAEs occurred in the monotherapy group.ConclusionsFruquintinib‐based therapy displayed an optimal tumor control and an acceptable safety profile in patients with advanced or metastatic sarcoma.